2023 World Conference on Lung Cancer (Posters)-EP12.02. PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer

EP12.02. PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study conducted at Shanghai Pulmonary Hospital in China aimed to investigate the association between the expression of programmed cell death-ligand 1 (PD-L1) and the effectiveness of alectinib in patients with ALK-rearranged lung cancer. The study evaluated the baseline PD-L1 expression in 56 treatment-naïve patients using immunohistochemistry. The patients' clinical characteristics, tumor responses, and survival outcomes were examined.<br /><br />The results showed that there was no statistically significant association between PD-L1 positivity and progression-free survival (PFS) in patients treated with alectinib. However, patients with high PD-L1 expression had a trend of longer PFS.<br /><br />Based on these findings, the study concluded that PD-L1 expression cannot predict the efficacy of alectinib as a front-line treatment for ALK-positive non-small cell lung cancer (NSCLC) patients. Additionally, PD-L1 expression may not serve as a predictive biomarker for the effectiveness of alectinib in this patient population.<br /><br />These findings are important as previous research has suggested that PD-L1 expression could be related to the effectiveness of other targeted therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) or the ALK TKI crizotinib. However, this study indicates that PD-L1 expression may not be a reliable indicator of the response to alectinib in ALK-positive lung cancer patients.<br /><br />It is worth noting that the study did not disclose any relevant financial relationships that could potentially influence the results.

Asset Subtitle

Xinyu Liu

Meta Tag

Speaker Xinyu Liu

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

Shanghai Pulmonary Hospital

China

programmed cell death-ligand 1

PD-L1

alectinib

ALK-rearranged lung cancer

immunohistochemistry

progression-free survival

non-small cell lung cancer

epidermal growth factor receptor